Navigation Links
Isis and Collaborators Present New Research at the ATVB Annual Conference
Date:5/1/2009

Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such products. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2008, which is on file with the SEC. Copies of this and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries, including Regulus Therapeutics Inc.

Isis Pharmaceuticals is a registered trademark of Isis Pharmaceuticals, Inc. Regulus Therapeutics is a trademark of Regulus Therapeutics Inc.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
2. Rosetta Genomics and Collaborators Identify MicroRNAs That Can Accurately Discriminate Between Primary and Metastatic Tumors in the Brain
3. Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
9. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
10. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
11. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... , March 3, 2015 Although lung ... the world, there are only 18 drugs in the ... Almita and Avastin are nearing their patent expiry in ... therapeutics market offers vast potential that drug manufacturers are ... treatment of small cell lung cancer (SCLC) and non-small ...
(Date:3/3/2015)... , March 3, 2015 ImmunoCellular Therapeutics, ... Andrew Gengos , Chief Executive Officer of ImmunoCellular, will ... 27 th Annual ROTH Conference on Tuesday, March ... Hotel, Laguna Niguel , CA.   ... the ROTH presentation, please log on through a link ...
(Date:3/3/2015)... , March 3, 2015 Chrono Therapeutics ... an investment by Rock Health , the leading ... of Chrono,s SmartStop™ programmable transdermal drug delivery system and ... Smoking kills more than 500,000 Americans each year, ... in the United States . Of ...
Breaking Medicine Technology:Targeted Lung Cancer Therapies Are Supplanting Conventional Treatments 2Targeted Lung Cancer Therapies Are Supplanting Conventional Treatments 3ImmunoCellular Therapeutics to Present at ROTH Conference on March 10th 2Chrono Therapeutics Receives Investment from Rock Health to Advance SmartStopTM Smoking Cessation Technology 2Chrono Therapeutics Receives Investment from Rock Health to Advance SmartStopTM Smoking Cessation Technology 3
... N.J., Sept. 28 Laureate Pharma, Inc., ... company, today announced the appointment of Steven ... Mr. Johnson will be responsible for Laureate,s ... business development and project management, supporting the ...
... JUNCTION, N.J., Sept. 28 Tamir Biotechnology, Inc. ... Corporation) announced today that scientists supported by the ... reported test results confirming two of our lead ... cell culture and plaque reduction assay (the gold ...
Cached Medicine Technology:Laureate Pharma Appoints Steven R. Johnson as Vice President, Business Development 2New Discovery Targets Cytomegalovirus (CMV) 2New Discovery Targets Cytomegalovirus (CMV) 3New Discovery Targets Cytomegalovirus (CMV) 4
(Date:3/3/2015)... Prophecy Healthcare®, Inc., the nation's ... testing, is now conducting dedicated research to expand ... of acquiring the exam rights and Intellectual Property ... the research will soon create more health care ... healthcare staffing organizations and more. , ...
(Date:3/3/2015)... 2015 Extend Nutrition, a leading nutritional snack ... of calories consumed at the next meal by an average ... are no lifestyle changes needed and no program to abide ... , The starter kit contains 60 servings of nutritional bars, ... protein, fiber, healthy fat and complex carbohydrates that helps to ...
(Date:3/3/2015)... 03, 2015 Getting to the truth of ... and well-being are at stake. So when it comes to ... move about pain-free – it’s vital to separate fact from ... resource, according to Sridhar Yalamanchili, PT, MSPT, and Director of ... A September 2014 nationwide survey by the American Physical Therapy ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 Human ... that it’s offering a new master health insurance plan ... its clients with a group platform removing potential cost ... Master Health Plan has been in effect since January ... clients with much need medical cost savings. , The ...
(Date:3/3/2015)... Sponsors of Medicare Advantage (MA) plans and stand-alone ... changes to sift through as a result of CMS’s ... Feb. 20. The potential pay changes alone are tough ... type and location of the plan’s membership. But there ... before CMS issues the final notice and when 2016 ...
Breaking Medicine News(10 mins):Health News:Prophecy Healthcare Acquires IP to Expand Behavioral Benchmarks 2Health News:Prophecy Healthcare Acquires IP to Expand Behavioral Benchmarks 3Health News:Snack Your Way to a Smaller Waistline with Extend Nutrition’s New “Snack-2-Health Kit” 2Health News:Snack Your Way to a Smaller Waistline with Extend Nutrition’s New “Snack-2-Health Kit” 3Health News:Separating Fact from Fiction about Physical Therapy 2Health News:Separating Fact from Fiction about Physical Therapy 3Health News:HCBR Group Offers Master Healthcare Plan through Humana 2Health News:March 12 Webinar to Analyze Implications of CMS’s ’45-Day Notice’ and 2016 Call Letter for MA and Part D Plans 2
... PORTLAND, Ore. Researchers at Oregon Health & Science University,s ... women at high-risk for ovarian cancer who also want to ... which serve as the "breeding ground" for ovarian cancer, may ... would be a vast improvement over the current prevention strategy ...
... HealthDay Reporter , WEDNESDAY, April 6 (HealthDay News) ... not to mention the Grim Reaper, a new study from ... go shopping daily live longer than their less shopping-prone peers. ... women, according to the study, which was published recently in ...
... TORONTO, Ont., April 7, 2011 Virtual reality and other ... according to research from St. Michael,s Hospital. Patients ... up to five times more likely to show improvements in ... "Virtual reality gaming is a promising and potentially ...
... doctors more accountable for health care quality, more attention must ... to evaluate caregivers, says a prominent Johns Hopkins patient safety ... Health Affairs , Peter J. Pronovost, M.D., Ph.D., a ... Hopkins University School of Medicine, argues that as the desire ...
... Biology and Medicine is pleased to announce the 2011 ... $500 travel grant for undergraduate/ graduate students and/or individuals ... members of the Society to attend the Experimental Biology ... of their research work which were evaluated by a ...
... three-year follow-up study of patients in the Hepatitis ... revealed that increased mortality among patients with advanced ... was attributed to non-liver related causes and occurred ... to this excess mortality was evident to researchers, ...
Cached Medicine News:Health News:Ovarian cancer finding may be a 'win-win' for at-risk women who wish to have a family 2Health News:'Retail Therapy' Might Really Work 2Health News:'Retail Therapy' Might Really Work 3Health News:Video games effective treatment for stroke patients: study 2Health News:Unreliable 'outcomes' measures hamper efforts to assure better, safer care 2Health News:Unreliable 'outcomes' measures hamper efforts to assure better, safer care 3Health News:SEBM Young Investigator Awards for 2011 2Health News:Increased mortality rates seen in chronic hepatitis C patients with pre-cirrhotic advanced fibrosis 2Health News:Increased mortality rates seen in chronic hepatitis C patients with pre-cirrhotic advanced fibrosis 3
... Our most popular onsite test! QuickScreen multi-panel ... urine sample, and your choice of any ... multi-panels offer total flexibility for your drug ... the specimen and the built-in timer tells ...
... The SureStep™ Drug Screen Tests are available ... for MDMA (Ecstasy). Designed using Microgenics Antibody ... the only point of care immunoassay targeted ... for both MDA and MDEA but no ...
Accu-Stat Home Drug Test for Marijuana (THC), Cocaine (COC), Amphetamine (AMP), Methamphetamine (mAMP), Opiates (OPI), and Phencyclidine (PCP)....
... drugs of abuse tests are highly accurate in ... recommended cut-off as confirmed by GC/MS testing. This ... specific alternative method (such as GC/MS) must be ... Professional judgment should be applied to any drug ...
Medicine Products: